This article discusses the role of mAbs in follicular lymphoma and marginal zone lymphoma along with reviewing the current data about the use of biosimilar mAbs in these diseases.
This editorial article provides an overview of the evolving healthcare landscape shaped by the entry of multiple biosimilars, including for a given reference product, and their impact on the healthsystem pharmacist with respect to formulary assessment, implementation, and education of various health-system stakeholders, including patients.
Biosimilar products are already approved and marketed in several countries. This review focuses on remaining challenges regarding biosimilars, such as the lack of regulatory harmony, especially concerning naming, the marketed intended copies, the interchangeability, and the biosimilars in orphan diseases.
